MENCONI, FRANCESCA Statistiche
MENCONI, FRANCESCA
DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE
Functional outcomes and complications in refractory dysthyroid optic neuropathy management: Experience with 3 different surgical protocols
2022-01-01 Dallan, I.; Cristofani-Mencacci, L.; Fiacchini, G.; Benettini, G.; Picariello, M.; Lanzolla, G.; Lazzerini, F.; Rocchi, R.; Turri-Zanoni, M.; Menconi, F.; Sellari-Franceschini, S.; Marino, M.
Role of the mononuclear cell infiltrate in Graves’ orbitopathy (GO): results of a large cohort study
2022-01-01 Rotondo Dottore, G.; Torregrossa, L.; Lanzolla, G.; Mariotti, S.; Menconi, F.; Piaggi, P.; Cristofani Mencacci, L.; Posarelli, C.; Maglionico, M. N.; Dallan, I.; Figus, M.; Nardi, M.; Marcocci, C.; Basolo, F.; Marinò, M.
Sirolimus as a second-line treatment for Graves' orbitopathy
2022-01-01 Lanzolla, G; Maglionico, M N; Comi, S; Menconi, F; Piaggi, P; Posarelli, C; Figus, M; Marcocci, C; Marino', Michele
Beneficial effect of low-dose radioiodine ablation for Graves’ orbitopathy: results of a retrospective study
2021-01-01 Lanzolla, G.; Menconi, F.; Nicoli, F.; Posarelli, C.; Maglionico, M. N.; Figus, M.; Nardi, M.; Marcocci, C.; Marino, M.
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial
2021-01-01 Lanzolla, Giulia; Sabini, Elena; Leo, Marenza; Menconi, Francesca; Rocchi, Roberto; Sframeli, Angela; Piaggi, Paolo; Nardi, Marco; Marcocci, Claudio; Marinò, Michele
Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study
2020-01-01 Perros, P.; Zarkovic, M. P.; Panagiotou, G. C.; Azzolini, C.; Ayvaz, G.; Baldeschi, L.; Bartalena, L.; Boschi, A. M.; Nardi, M.; Brix, T. H.; Covelli, D.; Daumerie, C.; Eckstein, A. K.; Fichter, N.; Ciric, S.; Hegedus, L.; Kahaly, G. J.; Konuk, O.; Lareida, J. J.; Okosieme, O. E.; Leo, M.; Mathiopoulou, L.; Clarke, L.; Menconi, F.; Morris, D. S.; Orgiazzi, J.; Pitz, S.; Salvi, M.; Muller, I.; Knezevic, M.; Wiersinga, W. M.; Curro, N.; Dayan, C. M.; Marcocci, C.; Marino, M.; Moller, L.; Pearce, S. H.; Toruner, F.; Bernard, M.; Perros, P.; Lareida, J. J.
Combined mycophenolate + prednisolone therapy is more effective than prednisolone in active and moderate-to-severe Graves’ Orbitopathy – A randomized, observer blind, multicenter trial
2018-01-01 Kahaly, Gj; Riedl, M; König, J; Pitz, S; Kampmann, E; Kolbe, E; Ponto, Ka; Diana, T; Eckstein, A; Müller, L; Führer, D; Salvi, M; Campi, I; Covelli, D; Curro, N; Leo, M; Marinò, M; Menconi, F; Marcocci, C; Bartalena, L; Perros, P; Wiersinga, Wm
High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study
2018-01-01 Sabini, Elena; Mazzi, Barbara; Profilo, Maria Antonietta; Mautone, Teresa; Casini, Giamberto; Rocchi, Roberto; Ionni, Ilaria; Menconi, Francesca; Leo, Marenza; Nardi, Marco; Vitti, Paolo; Marcocci, Claudio; Marinò, Michele
Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study
2018-01-01 Lanzolla, Giulia; Sabini, E.; Profilo, M. A.; Mazzi, B.; Sframeli, A.; Rocchi, R.; Menconi, F.; Leo, M.; Nardi, M.; Vitti, P.; Marcocci, C.; Marinò, M.
Selenium in Graves Hyperthyroidism and Orbitopathy
2018-01-01 Marinò, Michele; Menconi, Francesca; Rotondo Dottore, Giovanna; Leo, Marenza; Marcocci, Claudio
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy
2018-01-01 Marinò, M.; Rotondo Dottore, G.; Ionni, I.; Lanzolla, G.; Sabini, E.; Ricci, D.; Sframeli, A.; Mazzi, B.; Menconi, F.; Latrofa, F.; Vitti, P.; Marcocci, C.; Chiovato, L.
Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ orbitopathy (GO): a new frontier for GO treatment?
2017-01-01 Rotondo Dottore, G.; Ionni, I.; Menconi, F.; Casini, G.; Sellari-Franceschini, S.; Nardi, M.; Vitti, P.; Marcocci, C.; Marinò, M
Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves' orbitopathy (GO)
2017-01-01 Rotondo Dottore, G.; Ionni, I.; Menconi, F.; Casini, G.; Sellari-Franceschini, S.; Nardi, M.; Vitti, P.; Marcocci, C.; Marino', M.
Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients
2017-01-01 Leo, M.; Sabini, E.; Ionni, I.; Sframeli, A.; Mazzi, B.; Menconi, F.; Molinaro, E.; Bianchi, F.; Brozzi, F.; Santini, Pietro; Elisei, R.; Nardi, M.; Vitti, P.; Marcocci, C.; CACERES GARCIA DE MARINA, MARIA DE LA PALOMA
Use of low-dose radioiodine ablation for Gravesâ orbitopathy: results of a pilot, perspective study in a small series of patients
2017-01-01 Leo, M.; Sabini, E.; Ionni, I.; Sframeli, A.; Mazzi, B.; Menconi, F.; Molinaro, E.; Bianchi, F.; Brozzi, F.; Santini, P.; Elisei, R.; Nardi, M.; Vitti, P.; Marcocci, C.; Marinò, M.
Use of low-dose radioiodine ablation for Gravesâ orbitopathy: results of a pilot, perspective study in a small series of patients
2017-01-01 Leo, M.; Sabini, E.; Ionni, I.; Sframeli, A.; Mazzi, B.; Menconi, F.; Molinaro, E.; Bianchi, F.; Brozzi, F.; Santini, P.; Elisei, R.; Nardi, M.; Vitti, P.; Marcocci, C.; Marino', M.
Natural history of graves’ orbitopathy after treatment
2016-01-01 Menconi, Francesca; Leo, Marenza; Sabini, Elena; Mautone, Teresa; Nardi, Marco; Sainato, Aldo; SELLARI FRANCESCHINI, Stefano; Vitti, Paolo; Marcocci, Claudio; Marino', Michele
Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy
2016-01-01 Sabini, Elena; Sisti, Eleonora; Coco, B; Leo, Marenza; Ionni, Ilaria; Menconi, Francesca; Profilo, M. A; Mazzi, B; Rocchi, Roberto; Latrofa, Francesco; Vitti, Paolo; Brunetto, MAURIZIA ROSSANA; Marcocci, Claudio; Marino', Michele
VARIABLES AFFECTING THE LONG TERM OUTCOME OF GRAVES' ORBITOPATHY FOLLOWING HIGH DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY
2016-01-01 Leo, Marenza; Mautone, Teresa; Ionni, Ilaria; Profilo, MARIA ANTONIETTA; Sabini, Elena; Menconi, Francesca; Mazzi, Barbara; Rocchi, Roberto; Latrofa, Francesco; Nardi, Marco; Vitti, Paolo; Marcocci, Claudio; Marino', Michele
Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy
2015-01-01 Sisti, Eleonora; Coco, Barbara; Menconi, Francesca; Leo, Marenza; Rocchi, Roberto; Latrofa, Francesco; Profilo, MARIA ANTONIETTA; Mazzi, Barbara; Vitti, Paolo; Marcocci, Claudio; Brunetto, MAURIZIA ROSSANA; Marino', Michele
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Functional outcomes and complications in refractory dysthyroid optic neuropathy management: Experience with 3 different surgical protocols | 1-gen-2022 | Dallan, I.; Cristofani-Mencacci, L.; Fiacchini, G.; Benettini, G.; Picariello, M.; Lanzolla, G.; Lazzerini, F.; Rocchi, R.; Turri-Zanoni, M.; Menconi, F.; Sellari-Franceschini, S.; Marino, M. | |
| Role of the mononuclear cell infiltrate in Graves’ orbitopathy (GO): results of a large cohort study | 1-gen-2022 | Rotondo Dottore, G.; Torregrossa, L.; Lanzolla, G.; Mariotti, S.; Menconi, F.; Piaggi, P.; Cristofani Mencacci, L.; Posarelli, C.; Maglionico, M. N.; Dallan, I.; Figus, M.; Nardi, M.; Marcocci, C.; Basolo, F.; Marinò, M. | |
| Sirolimus as a second-line treatment for Graves' orbitopathy | 1-gen-2022 | Lanzolla, G; Maglionico, M N; Comi, S; Menconi, F; Piaggi, P; Posarelli, C; Figus, M; Marcocci, C; Marino', Michele | |
| Beneficial effect of low-dose radioiodine ablation for Graves’ orbitopathy: results of a retrospective study | 1-gen-2021 | Lanzolla, G.; Menconi, F.; Nicoli, F.; Posarelli, C.; Maglionico, M. N.; Figus, M.; Nardi, M.; Marcocci, C.; Marino, M. | |
| Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial | 1-gen-2021 | Lanzolla, Giulia; Sabini, Elena; Leo, Marenza; Menconi, Francesca; Rocchi, Roberto; Sframeli, Angela; Piaggi, Paolo; Nardi, Marco; Marcocci, Claudio; Marinò, Michele | |
| Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study | 1-gen-2020 | Perros, P.; Zarkovic, M. P.; Panagiotou, G. C.; Azzolini, C.; Ayvaz, G.; Baldeschi, L.; Bartalena, L.; Boschi, A. M.; Nardi, M.; Brix, T. H.; Covelli, D.; Daumerie, C.; Eckstein, A. K.; Fichter, N.; Ciric, S.; Hegedus, L.; Kahaly, G. J.; Konuk, O.; Lareida, J. J.; Okosieme, O. E.; Leo, M.; Mathiopoulou, L.; Clarke, L.; Menconi, F.; Morris, D. S.; Orgiazzi, J.; Pitz, S.; Salvi, M.; Muller, I.; Knezevic, M.; Wiersinga, W. M.; Curro, N.; Dayan, C. M.; Marcocci, C.; Marino, M.; Moller, L.; Pearce, S. H.; Toruner, F.; Bernard, M.; Perros, P.; Lareida, J. J. | |
| Combined mycophenolate + prednisolone therapy is more effective than prednisolone in active and moderate-to-severe Graves’ Orbitopathy – A randomized, observer blind, multicenter trial | 1-gen-2018 | Kahaly, Gj; Riedl, M; König, J; Pitz, S; Kampmann, E; Kolbe, E; Ponto, Ka; Diana, T; Eckstein, A; Müller, L; Führer, D; Salvi, M; Campi, I; Covelli, D; Curro, N; Leo, M; Marinò, M; Menconi, F; Marcocci, C; Bartalena, L; Perros, P; Wiersinga, Wm | |
| High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study | 1-gen-2018 | Sabini, Elena; Mazzi, Barbara; Profilo, Maria Antonietta; Mautone, Teresa; Casini, Giamberto; Rocchi, Roberto; Ionni, Ilaria; Menconi, Francesca; Leo, Marenza; Nardi, Marco; Vitti, Paolo; Marcocci, Claudio; Marinò, Michele | |
| Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study | 1-gen-2018 | Lanzolla, Giulia; Sabini, E.; Profilo, M. A.; Mazzi, B.; Sframeli, A.; Rocchi, R.; Menconi, F.; Leo, M.; Nardi, M.; Vitti, P.; Marcocci, C.; Marinò, M. | |
| Selenium in Graves Hyperthyroidism and Orbitopathy | 1-gen-2018 | Marinò, Michele; Menconi, Francesca; Rotondo Dottore, Giovanna; Leo, Marenza; Marcocci, Claudio | |
| Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy | 1-gen-2018 | Marinò, M.; Rotondo Dottore, G.; Ionni, I.; Lanzolla, G.; Sabini, E.; Ricci, D.; Sframeli, A.; Mazzi, B.; Menconi, F.; Latrofa, F.; Vitti, P.; Marcocci, C.; Chiovato, L. | |
| Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ orbitopathy (GO): a new frontier for GO treatment? | 1-gen-2017 | Rotondo Dottore, G.; Ionni, I.; Menconi, F.; Casini, G.; Sellari-Franceschini, S.; Nardi, M.; Vitti, P.; Marcocci, C.; Marinò, M | |
| Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves' orbitopathy (GO) | 1-gen-2017 | Rotondo Dottore, G.; Ionni, I.; Menconi, F.; Casini, G.; Sellari-Franceschini, S.; Nardi, M.; Vitti, P.; Marcocci, C.; Marino', M. | |
| Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients | 1-gen-2017 | Leo, M.; Sabini, E.; Ionni, I.; Sframeli, A.; Mazzi, B.; Menconi, F.; Molinaro, E.; Bianchi, F.; Brozzi, F.; Santini, Pietro; Elisei, R.; Nardi, M.; Vitti, P.; Marcocci, C.; CACERES GARCIA DE MARINA, MARIA DE LA PALOMA | |
| Use of low-dose radioiodine ablation for Gravesâ orbitopathy: results of a pilot, perspective study in a small series of patients | 1-gen-2017 | Leo, M.; Sabini, E.; Ionni, I.; Sframeli, A.; Mazzi, B.; Menconi, F.; Molinaro, E.; Bianchi, F.; Brozzi, F.; Santini, P.; Elisei, R.; Nardi, M.; Vitti, P.; Marcocci, C.; Marinò, M. | |
| Use of low-dose radioiodine ablation for Gravesâ orbitopathy: results of a pilot, perspective study in a small series of patients | 1-gen-2017 | Leo, M.; Sabini, E.; Ionni, I.; Sframeli, A.; Mazzi, B.; Menconi, F.; Molinaro, E.; Bianchi, F.; Brozzi, F.; Santini, P.; Elisei, R.; Nardi, M.; Vitti, P.; Marcocci, C.; Marino', M. | |
| Natural history of graves’ orbitopathy after treatment | 1-gen-2016 | Menconi, Francesca; Leo, Marenza; Sabini, Elena; Mautone, Teresa; Nardi, Marco; Sainato, Aldo; SELLARI FRANCESCHINI, Stefano; Vitti, Paolo; Marcocci, Claudio; Marino', Michele | |
| Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy | 1-gen-2016 | Sabini, Elena; Sisti, Eleonora; Coco, B; Leo, Marenza; Ionni, Ilaria; Menconi, Francesca; Profilo, M. A; Mazzi, B; Rocchi, Roberto; Latrofa, Francesco; Vitti, Paolo; Brunetto, MAURIZIA ROSSANA; Marcocci, Claudio; Marino', Michele | |
| VARIABLES AFFECTING THE LONG TERM OUTCOME OF GRAVES' ORBITOPATHY FOLLOWING HIGH DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY | 1-gen-2016 | Leo, Marenza; Mautone, Teresa; Ionni, Ilaria; Profilo, MARIA ANTONIETTA; Sabini, Elena; Menconi, Francesca; Mazzi, Barbara; Rocchi, Roberto; Latrofa, Francesco; Nardi, Marco; Vitti, Paolo; Marcocci, Claudio; Marino', Michele | |
| Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy | 1-gen-2015 | Sisti, Eleonora; Coco, Barbara; Menconi, Francesca; Leo, Marenza; Rocchi, Roberto; Latrofa, Francesco; Profilo, MARIA ANTONIETTA; Mazzi, Barbara; Vitti, Paolo; Marcocci, Claudio; Brunetto, MAURIZIA ROSSANA; Marino', Michele |